



(12) **EUROPEAN PATENT APPLICATION**

(43) Date of publication:  
**07.02.2001 Bulletin 2001/06**

(51) Int Cl.7: **C12N 15/12, C07K 14/495,  
A61K 38/18**

(21) Application number: **99115613.4**

(22) Date of filing: **06.08.1999**

(84) Designated Contracting States:  
**AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU  
MC NL PT SE**  
Designated Extension States:  
**AL LT LV MK RO SI**

(71) Applicant: **HyGene AG,**  
**c/o Mäder + Baumgartner Treuhand AG**  
**8121 Neuhausen am Rheinfall (CH)**

(72) Inventor: **The designation of the inventor has not  
yet been filed**

(74) Representative:  
**Böhm, Brigitte, Dipl.-Chem. Dr. et al**  
**Weickmann & Weickmann**  
**Patentanwälte**  
**Postfach 86 08 20**  
**81635 München (DE)**

(54) **Monomeric protein of the TGF-beta family**

(57) The present invention is concerned with proteins selected from the members of the TGF- $\beta$  superfamily, which are monomeric due to substitution or deletion of a cysteine which is responsible for dimer formation.

The invention is also concerned with nucleic acids,

encoding such monomeric proteins, vectors or host cells containing the nucleic acids as well as with pharmaceutical compositions comprising the proteins or nucleic acids encoding the proteins. The pharmaceutical compositions can be applied advantageously for all indications for which the respective dimeric proteins are useful.

## Description

**[0001]** The present invention concerns a biologically active protein from the TGF- $\beta$  superfamily, wherein this protein remains in monomeric form due to substitution or deletion of a cysteine which is responsible for the dimerization in the wild-type protein. Further the invention concerns a nucleic acid, which codes for a protein according to the invention, an expression vector containing such nucleic acid and a host cell, containing a corresponding nucleic acid or an expression vector, said nucleic acid being suitable for the expression of the protein. The invention also concerns a pharmaceutical composition containing the protein according to the invention or a nucleic acid coding therefor. The use of the pharmaceutical composition according to the invention concerns the prevention or treatment of all conditions which can also be treated with the dimeric form of the corresponding protein.

**[0002]** Many growth factors from the TGF- $\beta$  superfamily (Kingsley, *Genes and Development* 8, 133-146 (1994) as well as the references cited therein) are relevant for a wide range of medical treatment methods and applications which in particular concern promotion of cell proliferation and tissue formation, including wound healing and tissue reproduction. Such growth factors in particular comprise members of the TGF- $\beta$  (transforming growth factor, cf. e.g. Roberts and Sporn, *Handbook of Experimental Pharmacology* 95 (1990), page 419-472, editors: Sporn and Roberts), the DVR-group (Hötten et al., *Biochem. Biophys. Res. Comm.* 206 (1995), page 608-613 and further literature cited therein) including BMPs (bone morphogenetic protein, cf. e.g. Rosen and Thies, *Growth Factors in Perinatal Development* (1993), page 39-58, editors: Tsang, Lemons and Balistreri) and GDFs (growth differentiation factors), the inhibin/activin (cf. e.g. Vale et al., *The Physiology of Reproduction*, second edition (1994), page 1861-1878, editors: Knobil and Neill) and the GDNF protein family (Rosenthal, *Neuron* 22 (1999), page 201-203; Airaksinen et al. *Mol Cell Neurosci* 13 (1999), page 313-325). Although the members of the TGF- $\beta$  superfamily show high amino acid homologies in the mature part of the protein, in particular 7 conserved cysteines, they show considerable variations in their exact functions. Often individual growth factors of these families exhibit a plurality of functions at the same time, so that their application is of interest in various medical indications. Some of these multifunctional proteins also have survival promoting effects on neurons in addition to functions such as e.g. regulation of the proliferation and differentiation in many cell types (Roberts and Sporn, supra; Sakurai et al., *J. Biol. Chem.* 269 (1994), page 141 18-14122). Thus e.g. trophic effects on embryonic motoric and sensory neurons were demonstrated for TGF- $\beta$  in vitro (Martinou et al., *Devl. Brain Res.* 52, page 175-181 (1990) and Chalazonitis et al., *Dev. Biol.* 152, page 121-132 (1992)). In addition, effects promoting survival are shown for dopaminergic neurons of the mid-brain for the proteins TGF- $\beta$ -1, -2, -3, activin A and GDNF (glial cell line-derived neurotrophic factor), a protein which has structural similarities to TGF- $\beta$  superfamily members, these effects being not mediated via astrocytes (Kriegstein et al., *EMBO J.* 14, page 736-742 (1995)).

**[0003]** Interesting members of the TGF- $\beta$  superfamily or active variants thereof comprise the TGF- $\beta$  proteins like TGF- $\beta$ 1, TGF- $\beta$ 2, TGF- $\beta$ 3, TGF- $\beta$ 4, TGF- $\beta$ 5 (U.S. 5,284,763; EP 0376785; U.S. 4,886,747; DNA 7 (1988), page 1-8), EMBO J. 7 (1988), page 3737-3743), *Mol. Endo.* 2 (1988), page 1186-1195), *J. Biol. Chem.* 265 (1990), page 1089-1093), OP1, OP2 and OP3 proteins (U.S. 5,011,691, U.S. 5,652,337, WO 91/05802) as well as BMP2, BMP3, BMP4 (WO 88/00205, U.S. 5,013,649 and WO 89/10409, *Science* 242 (1988), page 1528-1534), BMP5, BMP6 and BMP-7 (OP1) (*Proc. Natl. Acad. Sci.* 87 (1990), page 9841-9847, WO 90/11366), BMP8 (OP2) (WO 91/18098), BMP9 (WO 93/00432), BMP10 (WO 94/26893), BMP11 (WO 94/26892), BMP12 (WO 95/16035), BMP13 (WO95/16035), BMP15 (WO 96/36710), BMP16 (WO.98/12322), BMP3b (*Biochem. Biophys. Res. Comm.* 219 (1996), page 656-662), GDF1 (WO 92/00382 and *Proc. Natl. Acad. Sci.* 88 (1991), page 4250-4254), GDF8 (WO 94/21681), GDF10 (WO95/10539), GDF11 1 (WO 96/01845), GDF5 (CDMP1, MP52) (WO 95/04819; WO96/01316; WO 94/15949, WO 96/14335 and WO 93/16099 and *Nature* 368 (1994), page 639-643), GDF6 (CDMP2, BMP13) (WO 95/01801, WO 96/14335 and WO95/16035), GDF7 (CDMP3, BMP12) (WO 95/01802 and WO 95/10635), GDF14 (WO 97/36926), GDF15 (WO 99/06445), GDF16 (WO 99/06556), 60A (*Proc. Natl. Acad. Sci.* 88 (1991), page 9214-9218), DPP (*Nature* 325 (1987), page 81-84), Vgr-1 (*Proc. Natl. Acad. Sci.* 86 (1989), page 4554-4558) Vg-1, (*Cell* 51 (1987), page 861-867), dorsalin (*Cell* 73 (1993), page 687-702), MIS (*Cell* 45 (1986), page 685-698), pCL13 (WO 97/00958), BIP (WO 94/01557), inhibin  $\alpha$ , activin  $\beta$ A and activin  $\beta$ B (EP 0222491), activin  $\beta$ C (MP121) (WO 96/01316), activin  $\beta$ E and GDF12 (WO 96/02559 and WO 98/22492), activin  $\beta$ D (*Biochem. Biophys. Res. Comm.* 210 (1995), page 581-588), GDNF (*Science* 260 (1993), page 1130-1132, WO 93/06116), Neurturin (*Nature* 384 (1996), page 467-470), Persephin (*Neuron* 20 (1998), page 245-253, WO 97/33911), Artemin (*Neuron* 21 (1998), page 1291-1302), Mic-1 (*Proc. Natl. Acad. Sci. USA* 94 (1997), page 11514-11519), Univin (*Dev. Biol.* 166 (1994), page 149-158), ADMP (*Development* 121 (1995), page 4293-4301), Nodal (*Nature* 361 (1993), page 543-547), Screw (*Genes Dev.* 8 (1994), page 2588-2601). Other useful proteins include biologically active biosynthetic constructs including biosynthetic proteins designed using sequences from two or more known morphogenetic proteins. Examples of biosynthetic constructs are disclosed in U.S. 5,011,691 (e.g. COP-1, COP-3, COP-4, COP-5, COP-7 and COP-16). The disclosure of the cited publications including patents or patent applications are incorporated herein by reference.

**[0004]** The occurrence of proteins of the TGF- $\beta$  superfamily in various tissuous stages and development stages corresponds with differences with regard to their exact functions as well as target sites, life span, requirements for auxiliary

factors, necessary cellular physiological environment and/or resistance to degradation.

**[0005]** The proteins of the TGF- $\beta$  superfamily exist as homodimers or heterodimers having a single disulfide bond. This disulfide bond is mediated by a specific and in most of the proteins conserved cysteine residue of the respective monomers. Up to now it was considered as indispensable for the biological activity that the protein is present in its dimeric form. Several publications indicated that biological activity can only be obtained for dimeric proteins and it was speculated that this dimer formation is important for further polymer formation of two or more dimers to achieve inter-cellular signal transmission by simultaneous binding to type I and type II receptors for the TGF- $\beta$  superfamily proteins on cells. It was assumed that only this simultaneous binding to both kinds of receptors would allow for effective inter-cellular signal transmission for the benefit of the patient (Bone, volume 19 (1996), page 569-574).

**[0006]** A disadvantage of the use of these proteins as medicaments and their production is, that they are not readily obtainable in biologically active and sufficiently pure form by recombinant expression in prokaryotes without intensive renaturation procedures.

**[0007]** Thus it was the object of the present invention to provide a simple and inexpensive possibility to reproducibly produce proteins exhibiting high biological activity, wherein this biological activity should essentially correspond to that of the dimers of the proteins of said families.

**[0008]** This object is solved according to the invention by a protein selected from the members of the TGF- $\beta$  protein superfamily, such protein being necessarily monomeric due to substitution or deletion of a cysteine which is responsible for dimeric formation.

**[0009]** Surprisingly it has been found that the substitution or deletion of the cysteine, which normally effects the dimerization in the proteins, results upon expression and correct folding (proper formation of the intramolecular disulfide bridges) in a monomeric protein that retains the biological activity of the dimeric form. Even more surprisingly, it was found that at least some of the monomeric proteins show a higher activity, based on the weight of protein, than their respective dimeric forms. Apart from this improved biological activity an important advantage for the proteins according to the invention is that they can be expressed in a large amount in prokaryotic hosts and upon simple refolding of the monomers they are obtained in high purity and very high yield without the need to separate dimerized from non-dimerized (monomeric) protein. The findings of the present invention are very surprising since, as already mentioned above, it was common understanding that only a dimer of the morphogenetic proteins has biological activity. Despite this understanding the proteins according to the invention show an up to two-fold higher activity than that of the dimer on the basis of protein weight. The smaller size of the proteins of the invention, while maintaining the biological activity, can also be considered as advantageous, e.g. for applications concerning the brain since the monomeric protein can much easier pass the blood-brain-barrier than the dimeric form.

**[0010]** The proteins according to the invention encompass all proteins of the mentioned protein families that are normally present in dimeric form. Also parts of such proteins that retain substantial activity or fusion proteins or precursor forms of proteins shall be considered as encompassed by the present invention as well as biologically active naturally occurring or biosynthetic variants of TGF- $\beta$  superfamily proteins, as long as they show at least considerable biological activity.

**[0011]** In a preferred embodiment of the present invention the monomeric protein is a mature protein or a biologically active part or variant thereof. The term "biologically active part or variant thereof" is meant to define either fragments retaining activity, precursor proteins that are e.g. cleaved at the site of activity to the mature form or show biological activity themselves, or also variants that still maintain essentially the biological activity of the wild-type protein. Such variants preferably contain conservative amino acid substitutions, but especially at the N-terminal part of the mature proteins even considerable deletions or substitutions do not lead to a considerable loss of biological activity. It is well within the skill of the man in the art to determine whether a certain protein shows the required biological activity. Proteins showing at least 70% and preferably at least 80% homology to the mature wild-type proteins of the above referenced protein families should be understood as encompassed by the present invention, as long as they contain the deletion or substitution of a cysteine, as required for the proteins according to the invention, and therefore do not form dimers.

**[0012]** It is especially preferred that proteins according to the invention contain at least the 7 cysteine region characteristic for the TGF- $\beta$  protein superfamily.

**[0013]** This specific 7 cysteine region is considered to be the most important part of the proteins in view of the biological activity. Therefore proteins retaining this critical region are preferred proteins according to the invention. It is disclosed in the state of the art which cysteine is responsible in a certain protein family or protein for dimer formation (see for example: Schlunegger & Grutter (1992) Nature 358, 430-434; Daopin et al., (1992) Science 257, 369-373 and Griffith et al., Proc. Natl. Acad. Sci. 93 (1996), page 878-883). This cysteine has to be deleted or substituted by another amino acid to form a protein according to the invention.

**[0014]** The 7 cysteine region is known for many proteins of the TGF- $\beta$  protein superfamily. In this region the respective location of the cysteine residues to each other is important and is only allowed to vary slightly in order not to lose the biological activity. Consensus sequences for such proteins are known in the state of the art and all proteins complying with such consensus sequences are considered to be encompassed by the present invention.

[0015] In an especially preferred embodiment of the present invention the protein contains a consensus sequence according to the following sequence

5 C (Y)<sub>25-29</sub> C Y Y Y C (Y)<sub>25-35</sub> X C (Y)<sub>27-34</sub> C Y C (Formula I),

wherein C denotes cysteine, Y denotes any amino acid including cysteine and X denotes any amino acid except cysteine.

10 [0016] More preferably the protein according to the invention contains a consensus sequence according to the following sequence

C (Y)<sub>28</sub> C Y Y Y C (Y)<sub>30-32</sub> X C (Y)<sub>31</sub> C Y C (Formula II),

15 wherein C, X and Y have the same meaning as defined above.

[0017] Even more preferably the protein according to the invention contains a consensus sequence according to the following sequence

20 C (X)<sub>28</sub> C X X X C (X)<sub>31-33</sub> C (X)<sub>31</sub> C X C (Formula III),

wherein C and X have the same meaning as defined above.

25 [0018] In these consensus sequences especially preferred distances between the respective cysteine residues are contained, wherein also already the dimer forming cysteine is substituted by another amino acid. As with all proteins of said protein superfamily the location of and distance between the cysteines is more important than the identity of the other amino acids contained in this region. Therefore, the consensus sequence shows the respective location of the cysteines, but does not show the identity of the other amino acids, since these other amino acids are widely variable in the proteins of the TGF- $\beta$  protein superfamily.

30 [0019] In a preferred embodiment of the present invention the monomeric protein according to the invention is a morphogenetic protein.

[0020] Most of the members of the TGF- $\beta$  protein superfamily are morphogenetic proteins that are useful for treatments where regulation of differentiation and proliferation of cells or progenitor cells is of interest. This can result in replacement of damaged and/or diseased tissue like for example skeletal (bone, cartilage) tissue, connective tissue, periodontal or dental tissue, neural tissue, tissue of the sensory system, liver, pancreas, cardiac, blood vessel and renal tissue, uterine or thyroid tissue etc. Morphogenetic proteins are often useful for the treatment of ulcerative or inflammatory tissue damage and wound healing of any kind such as enhanced healing of ulcers, burns, injuries or skin grafts. Especially preferred proteins according to the invention belong to the TGF- $\beta$ , BMP, GDF, activin or GDNF families. Several BMP proteins which were originally discovered by their ability to induce bone formation, have been described, as also indicated above. Meanwhile, several additional functions have been found as it is also true for members of the GDFs. These proteins show a very broad field of applications and especially are in addition to their bone and cartilage growth promoting activity (see for example: WO 88/00205, WO 90/11366, WO 91/05802) useful in periodontal disease, for inhibiting periodontal and tooth tissue loss, for sealing tooth cavities, for enhancing integration of a tooth in a tooth socket (see for example: WO 96/26737, WO 94/06399, WO 95/24210), for connective tissue such as tendon or ligament (see for example: WO 95/16035), for improving survival of neural cells, for inducing growth of neural cells and repairing neural defects, for damaged CNS tissue due to stroke or trauma (see for example: WO 97/34626, WO 94/03200, WO 95/05846), for maintaining or restoring sensory perception (see for example WO 98/20890, WO 98/20889), for renal failure (see for example: WO 97/41880, WO 97/41881), for liver regeneration (see for example WO 94/06449), for regeneration of myocardium (see for example WO 98/27995), for treatment or preservation of tissues or cells for organ or tissue transplantation, for integrity of gastrointestinal lining (see for example WO 94/06420), for increasing progenitor cell population as for example hematopoietic progenitor cells by *ex vivo* stimulation (see for example WO 92/15323), etc. One preferred member of the GDF family is the protein MP52 which is also termed GDF-5 or CDMP-1. Applications for MP52 reflect several of the already described applications for the BMP/GDF family. MP52 is considered to be a very effective promoter of bone and cartilage formation as well as connective tissue formation (see for example WO 95/04819, Hötten et al., (1996), Growth Factors 13, 65-74, Storm et al., (1994) Nature 368, 639-643, Chang et al., (1994) J. Biol. Chem. 269 (45), 28227-28234). In this connection MP52 is useful for applications concerning the joints between skeletal elements (see for example Storm & Kingsley (1996) Development 122, 3969-3979). One example for connective tissue is tendon and ligament (Wolfman et al., (1997), J. Clin. Invest.

100, 321-330, Aspenberg & Forslund (1999), Acta Orthop Scand 70, 51-54, WO 95/16035). MP52 is also useful for tooth (dental and periodontal) applications (see for example WO 95/04819, WO 93/16099, Morotome et al. (1998), Biochem. Biophys. Res. Comm. 244, 85-90). MP52 is useful in wound repair of any kind. It is in addition very useful for promoting tissue growth in the neuronal system and survival of dopaminergic neurons, for example. MP52 in this connection is useful for applications in neurodegenerative diseases like e.g. Parkinson's disease and possibly also Alzheimer's disease for Huntington chorea tissues (see for example WO 97/03188, Krieglstein et al., (1995) J. Neurosci. Res. 42, 724-732, Sullivan et al., (1997) Neurosci. Lett. 233, 73-76, Sullivan et al. (1998), Eur. J. Neurosci. 10, 3681-3688). MP52 allows to maintain nervous function or to retain nervous function in already damaged tissues. MP52 is therefore considered to be a generally applicable neurotrophic factor. It is also useful for diseases of the eye, in particular retina cornea and optic nerve (see for example WO 97/03188, You et al. (1999), Invest. Ophthalmol. Vis. Sci. 40, 296-311). The monomeric MP52 is expected to show all the already described activities of the dimeric form as well as some further described activities as described for the dimeric BMP/GDF family members. It is expected to be for example also useful for increasing progenitor cell populations and for stimulating differentiation of progenitor cells ex vivo. Progenitor cells can be cells which take part in the cartilage formation process or hematopoietic progenitor cells. It is also useful for damaged or diseased tissue where a stimulation of angiogenesis is advantageous (see for example: Yamashita et al. (1997), Exp. Cell Res. 235, 218-226).

[0021] An especially preferred protein according to the invention therefore is protein MP52 or a biologically active part or variant thereof. Like in the already above mentioned definition of these terms MP52 can e.g. be used in its mature form, however, it can also be used as a fragment thereof at least containing the 7 cysteine region or also in a precursory form. Deviations at the N-terminal part of mature MP52 do not affect its activity to a considerable degree. Therefore, substitutions, deletions or additions on the N-terminal part of the proteins are still within the scope of the present invention. It might be useful to add a peptide to the N-terminal part of the protein, e.g. for purification reasons. It might not be necessary to cleave off this added peptide after expression and purification of the protein. Additional peptides at the N- or C-terminal part of the protein may also serve for the targeting of the protein to special tissues such as nerve or bone tissue or for the penetration of the blood/brain barrier. Generally, also fusion proteins of a monomeric protein according to the invention and another peptide or group are considered within the scope of the present invention, wherein these other peptides or groups are directing the localization of the fusion protein, e.g. because of an affinity to a certain tissue type etc. Examples for such fusion proteins are described in WO 97/23612. The protein containing such addition will retain its biological activity at least as long as such addition does not impair the formation of the biologically active conformation of the protein.

[0022] In an especially preferred embodiment of the present invention the proteins comprises the amino acid sequence according to SEQ.ID.NO.1 (DNA and protein sequence) and SEQ.ID.No.2 (protein sequence, only), respectively. SEQ.ID.NO.2 shows the complete protein sequence of the prepro protein of human MP52, as already disclosed in WO 95/04819. The start of the mature protein lies preferably in the area of amino acids 352-400, especially preferred at amino acids 381 or 382. Therefore, the mature protein comprises amino acids 381-501 or 382-501. The first alanine of the mature protein can be deleted and the mature protein then preferably comprises amino acids 383-501. The cysteine at position 465 that is present in the already described dimeric MP52 protein is according to the invention either deleted or substituted by another amino acid. This deletion or substitution is represented by Xaa at the respective position in SEQ.ID.Nos.1 and 2.

[0023] The activin/inhibin family proteins are of interest for applications related to contraception, fertility and pregnancy (see for example WO 94/19455, U.S. 5,102,868). They are also of interest for applications like repair or prevention of diseases of the nervous system, they can be used in the repair of organ tissue such as liver and even in bone and cartilage, too. In this connection MP121 (activin  $\beta$ C) is especially useful in applications for growth or regeneration of damaged and/or diseased tissue, especially the liver tissue, neural tissue, skeletal tissue (see for example WO 96/01316, WO 98/22492 and WO 97/03188). MP121 is known to be predominantly expressed in the liver whereby the mRNA is markedly reduced after partial hepatectomy. MP121 is expected to regulate the liver mass (Zhang et al., Endocrine Journal 44 (1997), page 759-764). The monomeric MP121 shows all the already described activities of the dimeric form as well as some further described activities as described for the dimeric TGF- $\beta$  superfamily members. It is for example also expected to be useful in treatment of ulceration (for example stomach ulceration) and useful for integrity of gastrointestinal lining and for stimulating differentiation of progenitor cells ex vivo, treatment or preservation of mammalian tissue or cells, e.g. for organ or tissue transplantation.

[0024] A further preferred protein according to the invention therefore is MP121, a member of the activin/inhibin protein family. Also for this protein a biologically active part or variant thereof is encompassed by the present invention according to the above defined rules. An especially preferred embodiment is shown in SEQ.ID.NO.3 (DNA and protein sequence) and SEQ.ID.NO.4 (protein sequence, only) respectively. SEQ.ID.NO.4 shows the complete amino acid sequence of the prepro protein of human MP121, that has already been disclosed in WO 96/01316. The start of the mature protein lies preferably between amino acids 217 and 247, most preferred at amino acid 237. A preferred mature protein therefore comprises the mature part of the protein starting at amino acid 237 and ending at amino acid 352.

However, also the precursor protein comprising the whole shown amino acid sequence is encompassed by the present invention. The cysteine at position 316 is according to the invention either deleted or substituted by another amino acid, being represented by Xaa in SEQ.ID.Nos.3 and 4.

**[0025]** The amino acid by which the cysteine residue effecting the dimerization is substituted can be selected by any amino acid that does not impair the formation of a biologically active conformation. The amino acid is preferably selected from the group of alanine, serine, threonine, leucine, isoleucine, glycine and valine.

**[0026]** The proteins according to the invention are in summary characterized by the absence of the cysteine residue in the amino acid sequence responsible for the dimer formation. This absence can be effected by substitution of this cysteine by another amino acid or by deletion. In case of deletion, however, it must be assured for the protein that the formation of the biologically active conformation is not hindered. The same is true for the selection of the substitution amino acid, wherein it is preferred to use an amino acid which has a form similar to cysteine.

**[0027]** The monomeric proteins according to the invention can be easily produced, in particular by expression in prokaryotes and renaturation according to known methods. It is advantageous that the protein can be obtained in exceedingly biologically active form. The proteins exhibit in monomeric form about the same activity as the dimer so that based on the amount of active substance only half of the monomeric protein has to be used in order to obtain the same positive biological effects.

**[0028]** A further subject matter of the present invention is a nucleic acid encoding a protein according to the invention. It is obvious that the nucleic acid has to have such a sequence that a deletion or substitution of the cysteine responsible for the dimer formation is achieved. The nucleic acid can be a naturally occurring nucleic acid, but also a recombinantly produced or processed nucleic acid. The nucleic acid can be both a DNA sequence and an RNA sequence, as long as the protein according to the invention can be obtained from this nucleic acid upon expression in a suitable system.

**[0029]** In a preferred embodiment of the invention the nucleic acid is a DNA sequence. This DNA sequence in an especially preferred embodiment of the invention comprises a sequence as shown in SEQ.ID.NO.1 and SEQ.ID.NO.3, respectively, or parts thereof. SEQ.ID.NO.1 shows a nucleic acid encoding MP52, wherein the codon for the cysteine responsible for the dimer formation is replaced by another codon which does not encode cysteine or deleted. This substitution or deletion is shown as "nnn" in the sequence protocols. SEQ.ID.NO.3 shows a nucleic acid encoding MP121, wherein also the codon for the cysteine effecting the dimer formation is replaced by a respective different codon or deleted. Instead of the complete sequences of SEQ.ID.NOs.1 or 3 also parts can be used that encode the mature proteins or fragments also described above.

**[0030]** It is preferred in the framework of the present invention that the nucleic acid apart from the coding sequences also contains expression control sequences. Such expression control sequences are known to the man skilled in the art and serve to control the expression of the encoded protein in a host cell. The host cell does not have to be an isolated cell, moreover, the nucleic acid can be expressed in the patient in vivo in the target tissue. This can be done by inserting the nucleic acid into the cell genome, however, it is also possible to transform host cells with expression vectors containing a nucleic acid according to the invention. Such expression vectors are a further subject matter of the present invention, wherein the nucleic acid is inserted in a suitable vector system, the vector system being selected according to the desired expression of the protein. The vector system can be a eukaryotic vector system, but - in the framework of the present invention - it is preferably a prokaryotic vector system, with which the proteins can be produced in prokaryotic host cells in a particularly easy and pure manner. In addition, the expression vector can be a viral vector.

**[0031]** Also host cells in turn are a further subject matter of the present invention. The host cells are characterized in that they contain a nucleic acid according to the invention or an expression vector according to the invention and that they are able to use the information present in the nucleic acids and in the expression vector, respectively, for the expression of a monomeric protein according to the invention.

**[0032]** Although in the framework of the present invention also eukaryotic host cells are suitable for the production of the protein, it is, as mentioned already several times above, particularly advantageous that the protein according to the invention can be produced in prokaryotic host cells, which therefore represent a preferred embodiment of the present invention.

**[0033]** After such preferred expression in prokaryotic host cells the protein is purified and renatured according to known methods, thereby effecting intramolecular cystine bridge formation.

**[0034]** Since, however, not only in vitro production of the monomeric protein is possible, but also in vivo expression of a nucleic acid according to the invention, a further preferred embodiment is a eukaryotic host cell, and especially a eukaryotic host cell containing the DNA in its genome, or as an expression vector. Such host cell can also be useful for application to an individual in need of morphogenic treatment.

**[0035]** Further subject matters of the present application are pharmaceutical compositions comprising at least one monomeric protein according to the invention or at least one nucleic acid encoding for such a protein or at least one corresponding expression vector, or at least one eukaryotic host cell expressing the monomeric protein.

**[0036]** The protein itself, but also a nucleic acid according to the invention, an expression vector or a host cell can be considered to be advantageous as active substances in a pharmaceutical composition. Also combinations of mon-

omeric proteins, with either biological activities in the same or different applications, can be used in preferred pharmaceutical compositions. Especially preferred for neuronal applications are combinations of MP52 with other TGF- $\beta$  superfamily proteins, both in monomeric form, like for example with GDNF (see WO 97/03188). Also preferred for neuronal applications are combinations of TGF- $\beta$  with GDNF, both in monomeric form. Also for applications concerning cartilage and/or bone the combination of several monomeric proteins might be useful, like MP52 with a protein of TGF- $\beta$  (see e.g. WO 92/09697) or MP52 with a cartilage maintenance-inducing protein such as BMP-9 (see e.g. WO 96/39170). When a nucleic acid or an expression vector is used, however, it has to be ensured that when administering to the patient there has to be an environment in which the nucleic acid and the expression vector, respectively, can be expressed and the protein according to the invention can be produced in vivo at the site of action. The same applies accordingly to the host cell according to the invention. When using expression vectors or host cells it is also possible that they encode more than one monomeric protein of the invention to produce a combination of two or more monomeric proteins.

**[0037]** It is advantageous to both the protein and the nucleic acid or the expression vector or the host cell when they are applied in and/or on a biocompatible matrix. The matrix material can be transplanted into the patient, e.g. surgically, wherein the protein either is effective on the surface of the matrix material or the protein or the DNA encoding the protein can be slowly released from the matrix material and then be effective over a long period of time. Additionally it is possible and advantageous to use a biodegradable matrix material in the pharmaceutical composition, wherein this material preferably dissolves during the protein induced tissue formation so that a protein or a nucleic acid contained therein is released and the newly formed tissue replaces the matrix material.

**[0038]** Finally, in case of applications relating to bone formation, it is advantageous to use a matrix material which is itself e.g. osteogenically active. By using such a matrix material it becomes possible to achieve a synergistic effect of protein and matrix material and to effect a particularly rapid and effective bone formation.

**[0039]** An especially preferred matrix material that can be used according to the invention is a matrix material as described in U.S. 5,231,169 and U.S. 5,776,193 and especially for applications like spinal fusion.

**[0040]** When using a combination of a matrix material and protein and/or nucleic acid and/or expression vector, it is preferable to sterilize such a combination prior to its use. The matrix and the morphogenetic protein can be separately sterilized and then combined, but it is preferred to terminally sterilize the device consisting of matrix and morphogenetic protein. Terminal sterilization can be achieved by ionizing radiation as already described for dimeric proteins (U.S. 5,674,292) but it is also advantageous to use ethylene oxide.

**[0041]** Of course this invention also comprises pharmaceutical compositions containing further substances like e.g. pharmacologically acceptable auxiliary and carrier substances. However, the protein according to the invention, also in case a matrix material is used, does not necessarily have to be used together with this matrix material, but can also be administered systemically, wherein it concentrates preferably in the surrounding of an implanted matrix material.

**[0042]** For some applications the protein according to the invention and the nucleic acid forming this protein, respectively or the expression vector or host cell can preferably be present in an injectable composition. Implants are not necessary or possible for every form of application of the proteins according to the invention. However, it is also possible to provide an implantable vessel or an implantable micropump containing for example semipermeable membranes in which the protein according to the invention or the nucleic acid generating it is contained, from which either one is slowly released over a prolonged period of time. The pharmaceutical composition according to the invention can also contain other vehicles which make it possible that the proteins or the nucleic acids or the expression vectors encoding these proteins be transported to the site of activity and released there, wherein e.g. liposomes or nanospheres can be used. In principle, it is also possible to apply host cells, like e.g. implanted embryonic cells expressing the proteins. Cells transfected with recombinant DNA may be encapsulated prior to implantation. Any other practicable but herein not explicitly described form of application of the pharmaceutical composition according to the invention and their corresponding manufacture are also comprised by the present invention, as long as they contain a protein according to the invention or a nucleic acid or an expression vector coding therefor, or a host cell expressing it.

**[0043]** Although the indications shall not be restricted herein and all indications exhibiting the dimeric form of the protein according to the invention are also comprised, in the following types of application for the compositions according to the invention are listed which are considered to be particularly preferred indications for the proteins of the present invention. On the one hand, there is the prevention or therapy of diseases associated with bone and/or cartilage damage or affecting bone and/or cartilage disease, or generally situations, in which cartilage and/or bone formation is desirable or for spinal fusion, and on the other hand, there is prevention or therapy of damaged or diseased tissue associated with connective tissue including tendon and/or ligament, periodontal or dental tissue including dental implants, neural tissue including CNS tissue and neuropathological situations, tissue of the sensory system, liver, pancreas, cardiac, blood vessel, renal, uterine and thyroid tissue, skin, mucous membranes, endothelium, epithelium, for promotion or induction of nerve growth, tissue regeneration, angiogenesis, wound healing including ulcers, burns, injuries or skin grafts, induction of proliferation of progenitor cells or bone marrow cells, for maintenance of a state of proliferation or differentiation for treatment or preservation of tissue or cells for organ or tissue transplantation, for integrity of gastroin-

testinal lining, for treatment of disturbances in fertility, contraception or pregnancy.

**[0044]** Diseases concerning sensory organs like the eye are also to be included in the preferred indication of the pharmaceutical composition according to the invention. As neuronal diseases again Parkinson's and Alzheimer's diseases can be mentioned as examples.

**[0045]** The pharmaceutical compositions according to the invention can be used in any desired way, the pharmaceutical compositions are formulated preferably for surgical local application, topical or systemic application. Auxiliary substances for the individual application form can of course be present in the pharmaceutical composition according to the invention. For some applications it can be advantageous to add some further substances to the pharmaceutical composition as for example Vitamin D (WO 92/21365), parathyroid hormone related peptide (WO 97/35607), chordin (WO 98/21335), anti-fibrinolytic agent (EP 535091), anti-metabolites (WO 95/09004), alkyl cellulose (WO 93/00050), mannitol (WO 98/33514), sugar, glycine, glutamic acid hydrochloride (U.S. 5,385,887), antibiotics, antiseptics, amino acids and/or additives which improve the solubility or stability of the monomeric morphogenetic protein as for example nonionic detergents (e.g. Tween 80), basic amino acids, carrier proteins (e.g. serum albumin), full length propeptides of the TGF- $\beta$  superfamily or parts thereof.

**[0046]** As can be already gathered from the description of proteins, nucleic acids and pharmaceutical compositions, the proteins according to the invention and respective nucleic acids, which provide for an expression of the proteins at the site of activity, can advantageously be applied in all areas for which also the dimeric forms of the proteins, as described, can be applied. In the framework of the present invention therefore a further subject matter is the use of a pharmaceutical composition according to the present invention for the treatment or prevention of any indications of the dimeric forms of the proteins according to the invention.

**[0047]** Herein it is again possible to conduct surgical operations and to implant the pharmaceutical composition (in particular contained on a matrix material), an administration in liquid or otherwise suitable form via, e.g. injection or oral administration seems to be as suitable as a topical application for e.g. tissue regeneration.

**[0048]** Fig. 1A shows a two dimensional graph of the conformation of recombinantly produced dimeric MP52 with the deleted first alanine. In this figure the 7 cysteine bridges contained in a dimer are shown, wherein there are 3 intramolecular cystine bridges per monomer unit and 1 intermolecular cystine bridge connecting both monomers. Fig. 1B shows the monomeric protein according to the invention wherein the cysteine of the amino acid sequence of MP52 has been replaced by X that denotes any amino acid except cysteine.



EP 1 074 620 A1

SEQUENCE LISTING

5 <110> HyGene AG

<120> Monomeric Protein of the TGF-beta Family

10 <130> 20780PEP Monomeric TGF-beta protein

<140>

15 <141>

<160> 4

20 <170> PatentIn Ver. 2.1

<210> 1

<211> 2703

25 <212> DNA

<213> Homo sapiens

<220>

30 <221> CDS

<222> (640)..(2142)

<400> 1

35 ccatggcctc gaaagggcag cggtgatttt ttccacataa atatatcgca cttaaatgag 60

tttagacagc atgacatcag agagtaatta aattggtttg gggtggaatt ccgtttccaa 120

40 ttcttgagtt caggtttgta aaagattttt ctgagcacct gcaggcctgt gagtgtgtgt 180

45 gtgtgtgtgt gtgtgtgtgt gtgtgtgtga agtattttca ctggaaagga ttcaaaacta 240

50 gggggaaaaa aaaactggag cacacaggca gcattacgcc attcttcctt cttggaaaaa 300

55 tccctcagcc ttatacaagc ctccctcaag ccttcagtca gttgtgcagg agaaaggggg 360

EP 1 074 620 A1

cggttggett tctcctttca agaacgagtt attttcagct gctgactgga gacggtgcac 420

5 gtctggatac gagagcattt ccactatggg actggataca aacacacacc cggcagactt 480

10 caagagtctc agactgagga gaaagccttt ccttctgctg ctactgctgc tgccgctgct 540

tttgaaagtc cactcctttc atgggttttc ctgccaaacc agaggcacct ttgctgctgc 600

15 cgctgttctc tttggtgtca ttcagcggct ggccagagg atg aga ctc ccc aaa 654

20 Met Arg Leu Pro Lys  
1 5

ctc ctc act ttc ttg ctt tgg tac ctg gct tgg ctg gac ctg gaa ttc 702

25 Leu Leu Thr Phe Leu Leu Trp Tyr Leu Ala Trp Leu Asp Leu Glu Phe  
10 15 20

atc tgc act gtg ttg ggt gcc cct gac ttg ggc cag aga ccc cag ggg 750

30 Ile Cys Thr Val Leu Gly Ala Pro Asp Leu Gly Gln Arg Pro Gln Gly  
25 30 35

35 acc agg cca gga ttg gcc aaa gca gag gcc aag gag agg ccc ccc ctg 798

Thr Arg Pro Gly Leu Ala Lys Ala Glu Ala Lys Glu Arg Pro Pro Leu  
40 45 50

40 gcc cgg aac gtc ttc agg cca ggg ggt cac agc tat ggt ggg ggg gcc 846

Ala Arg Asn Val Phe Arg Pro Gly Gly His Ser Tyr Gly Gly Gly Ala  
45 55 60 65

acc aat gcc aat gcc agg gca aag gga ggc acc ggg cag aca gga ggc 894

50 Thr Asn Ala Asn Ala Arg Ala Lys Gly Gly Thr Gly Gln Thr Gly Gly  
70 75 80 85

ctg aca cag ccc aag aag gat gaa ccc aaa aag ctg ccc ccc aga ccg 942

55 Leu Thr Gln Pro Lys Lys Asp Glu Pro Lys Lys Leu Pro Pro Arg Pro

EP 1 074 620 A1

|    | 90  | 95  | 100 |      |
|----|---|-----|-----|------|
| 5  | ggc ggc cct gaa ccc aag cca gga cac cct ccc caa aca agg cag gct |     |     | 990  |
|    | Gly Gly Pro Glu Pro Lys Pro Gly His Pro Pro Gln Thr Arg Gln Ala |     |     |      |
|    | 105   | 110 | 115 |      |
| 10 | aca gcc cgg act gtg acc cca aaa gga cag ctt ccc gga ggc aag gca |     |     | 1038 |
|    | Thr Ala Arg Thr Val Thr Pro Lys Gly Gln Leu Pro Gly Gly Lys Ala |     |     |      |
|    | 120   | 125 | 130 |      |
| 15 | ccc cca aaa gca gga tct gtc ccc agc tcc ttc ctg ctg aag aag gcc |     |     | 1086 |
|    | Pro Pro Lys Ala Gly Ser Val Pro Ser Ser Phe Leu Leu Lys Lys Ala |     |     |      |
| 20 | 135   | 140 | 145 |      |
|    | agg gag ccc ggg ccc cca cga gag ccc aag gag ccg ttt cgc cca ccc |     |     | 1134 |
| 25 | Arg Glu Pro Gly Pro Pro Arg Glu Pro Lys Glu Pro Phe Arg Pro Pro |     |     |      |
|    | 150   | 155 | 160 | 165  |
|    | ccc atc aca ccc cac gag tac atg ctc tgc ctg tac agg acg ctg tcc |     |     | 1182 |
| 30 | Pro Ile Thr Pro His Glu Tyr Met Leu Ser Leu Tyr Arg Thr Leu Ser |     |     |      |
|    | 170   | 175 | 180 |      |
| 35 | gat gct gac aga aag gga ggc aac agc agc gtg aag ttg gag gct ggc |     |     | 1230 |
|    | Asp Ala Asp Arg Lys Gly Gly Asn Ser Ser Val Lys Leu Glu Ala Gly |     |     |      |
|    | 185   | 190 | 195 |      |
| 40 | ctg gcc aac acc atc acc agc ttt att gac aaa ggg caa gat gac cga |     |     | 1278 |
|    | Leu Ala Asn Thr Ile Thr Ser Phe Ile Asp Lys Gly Gln Asp Asp Arg |     |     |      |
| 45 | 200   | 205 | 210 |      |
|    | ggc ccc gtg gtc agg aag cag agg tac gtg ttt gac att agt gcc ctg |     |     | 1326 |
| 50 | Gly Pro Val Val Arg Lys Gln Arg Tyr Val Phe Asp Ile Ser Ala Leu |     |     |      |
|    | 215   | 220 | 225 |      |
|    | gag aag gat ggg ctg ctg ggg gcc gag ctg cgg atc ttg cgg aag aag |     |     | 1374 |
| 55 | Glu Lys Asp Gly Leu Leu Gly Ala Glu Leu Arg Ile Leu Arg Lys Lys |     |     |      |

EP 1 074 620 A1

|    |   |      |     |     |  |
|----|---|------|-----|-----|--|
|    | 230   | 235  | 240 | 245 |  |
| 5  | ccc tgc gac acg gcc aag cca gcg gcc ccc gga ggc ggg cgg gct gcc | 1422 |     |     |  |
|    | Pro Ser Asp Thr Ala Lys Pro Ala Ala Pro Gly Gly Gly Arg Ala Ala |      |     |     |  |
|    | 250   | 255  | 260 |     |  |
| 10 | cag ctg aag ctg tcc agc tgc ccc agc ggc cgg cag ccg gcc tcc ttg | 1470 |     |     |  |
|    | Gln Leu Lys Leu Ser Ser Cys Pro Ser Gly Arg Gln Pro Ala Ser Leu |      |     |     |  |
| 15 | 265   | 270  | 275 |     |  |
|    | ctg gat gtg cgc tcc gtg cca ggc ctg gac gga tct ggc tgg gag gtg | 1518 |     |     |  |
| 20 | Leu Asp Val Arg Ser Val Pro Gly Leu Asp Gly Ser Gly Trp Glu Val |      |     |     |  |
|    | 280   | 285  | 290 |     |  |
|    | ttc gac atc tgg aag ctc ttc cga aac ttt aag aac tgc gcc cag ctg | 1566 |     |     |  |
| 25 | Phe Asp Ile Trp Lys Leu Phe Arg Asn Phe Lys Asn Ser Ala Gln Leu |      |     |     |  |
|    | 295   | 300  | 305 |     |  |
| 30 | tgc ctg gag ctg gag gcc tgg gaa cgg ggc agg gcc gtg gac ctc cgt | 1614 |     |     |  |
|    | Cys Leu Glu Leu Glu Ala Trp Glu Arg Gly Arg Ala Val Asp Leu Arg |      |     |     |  |
|    | 310   | 315  | 320 | 325 |  |
| 35 | ggc ctg ggc ttc gac cgc gcc gcc cgg cag gtc cac gag aag gcc ctg | 1662 |     |     |  |
|    | Gly Leu Gly Phe Asp Arg Ala Ala Arg Gln Val His Glu Lys Ala Leu |      |     |     |  |
| 40 | 330   | 335  | 340 |     |  |
|    | ttc ctg gtg ttt ggc cgc acc aag aaa cgg gac ctg ttc ttt aat gag | 1710 |     |     |  |
| 45 | Phe Leu Val Phe Gly Arg Thr Lys Lys Arg Asp Leu Phe Phe Asn Glu |      |     |     |  |
|    | 345   | 350  | 355 |     |  |
|    | att aag gcc cgc tct ggc cag gac gat aag acc gtg tat gag tac ctg | 1758 |     |     |  |
| 50 | Ile Lys Ala Arg Ser Gly Gln Asp Asp Lys Thr Val Tyr Glu Tyr Leu |      |     |     |  |
|    | 360   | 365  | 370 |     |  |
| 55 | ttc agc cag cgg cga aaa cgg cgg gcc cca ctg gcc act cgc cag ggc | 1806 |     |     |  |
|    | Phe Ser Gln Arg Arg Lys Arg Arg Ala Pro Leu Ala Thr Arg Gln Gly |      |     |     |  |

EP 1 074 620 A1

375 380 385

5 aag cga ccc agc aag aac ctt aag gct cgc tgc agt cgg aag gca ctg 1854

Lys Arg Pro Ser Lys Asn Leu Lys Ala Arg Cys Ser Arg Lys Ala Leu  
390 395 400 405

10 cat gtc aac ttc aag gac atg ggc tgg gac gac tgg atc atc gca ccc 1902

His Val Asn Phe Lys Asp Met Gly Trp Asp Asp Trp Ile Ile Ala Pro  
410 415 420

15 ctt gag tac gag gct ttc cac tgc gag ggg ctg tgc gag ttc cca ttg 1950

Leu Glu Tyr Glu Ala Phe His Cys Glu Gly Leu Cys Glu Phe Pro Leu  
20 425 430 435

cgc tcc cac ctg gag ccc acg aat cat gca gtc atc cag acc ctg atg 1998

25 Arg Ser His Leu Glu Pro Thr Asn His Ala Val Ile Gln Thr Leu Met  
440 445 450

aac tcc atg gac ccc gag tcc aca cca ccc acc nnn tgt gtg ccc acg 2046

30 Asn Ser Met Asp Pro Glu Ser Thr Pro Pro Thr Xaa Cys Val Pro Thr  
455 460 465

35 cgg ctg agt ccc atc agc atc ctc ttc att gac tct gcc aac aac gtg 2094

Arg Leu Ser Pro Ile Ser Ile Leu Phe Ile Asp Ser Ala Asn Asn Val  
470 475 480 485

40 gtg tat aag cag tat gag gac atg gtc gtg gag tcg tgt ggc tgc agg 2142

Val Tyr Lys Gln Tyr Glu Asp Met Val Val Glu Ser Cys Gly Cys Arg  
45 490 495 500

tagcagcact ggccctctgt cttctctgggt ggcacatccc aagagcccct tctgcactc 2202

50 ctggaatcac agaggggtca ggaagctgtg gcaggagcat ctacacagct tgggtgaaag 2262

55 gggattccaa taagcttgct cgctctctga gtgtgacttg ggctaaaggc ccccttttat 2322

EP 1 074 620 A1

ccacaagttc ccctggctga ggattgctgc ccgtctgctg atgtgaccag tggcaggcac 2382

5 aggtccaggg agacagactc tgaatgggac tgagtcccag gaaacagtgc tttccgatga 2442

10 gactcagccc accatttctc ctcacctggg ccttctcagc ctctggactc tctaagcac 2502

ctctcaggag agccacaggt gccactgcct cctcaaatca catttgtgcc tggtgacttc 2562

15 ctgtccctgg gacagttgag aagctgactg ggcaagagtg ggagagaaga ggagagggct 2622

20 tggatagagt tgaggagtgt gaggctgtta gactgttaga tttaaagtga tattgatgag 2682

ataaaaagca aaactgtgcc t 2703

25

<210> 2

30 <211> 501

<212> PRT

<213> Homo sapiens

35 <400> 2

Met Arg Leu Pro Lys Leu Leu Thr Phe Leu Leu Trp Tyr Leu Ala Trp

1 5 10 15

40 Leu Asp Leu Glu Phe Ile Cys Thr Val Leu Gly Ala Pro Asp Leu Gly

20 25 30

Gln Arg Pro Gln Gly Thr Arg Pro Gly Leu Ala Lys Ala Glu Ala Lys

45 35 40 45

Glu Arg Pro Pro Leu Ala Arg Asn Val Phe Arg Pro Gly Gly His Ser

50 55 60

50 Tyr Gly Gly Gly Ala Thr Asn Ala Asn Ala Arg Ala Lys Gly Gly Thr

65 70 75 80

55 Gly Gln Thr Gly Gly Leu Thr Gln Pro Lys Lys Asp Glu Pro Lys Lys

85 90 95

EP 1 074 620 A1

|    |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |  |
|----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|--|
|    | Leu | Pro | Pro | Arg | Pro | Gly | Gly | Pro | Glu | Pro | Lys | Pro | Gly | His | Pro | Pro |  |
|    |     |     |     | 100 |     |     |     |     | 105 |     |     |     |     | 110 |     |     |  |
| 5  | Gln | Thr | Arg | Gln | Ala | Thr | Ala | Arg | Thr | Val | Thr | Pro | Lys | Gly | Gln | Leu |  |
|    |     |     | 115 |     |     |     |     | 120 |     |     |     |     | 125 |     |     |     |  |
| 10 | Pro | Gly | Gly | Lys | Ala | Pro | Pro | Lys | Ala | Gly | Ser | Val | Pro | Ser | Ser | Phe |  |
|    |     | 130 |     |     |     |     | 135 |     |     |     |     | 140 |     |     |     |     |  |
| 15 | Leu | Leu | Lys | Lys | Ala | Arg | Glu | Pro | Gly | Pro | Pro | Arg | Glu | Pro | Lys | Glu |  |
|    | 145 |     |     |     |     | 150 |     |     |     |     | 155 |     |     |     |     | 160 |  |
| 20 | Pro | Phe | Arg | Pro | Pro | Pro | Ile | Thr | Pro | His | Glu | Tyr | Met | Leu | Ser | Leu |  |
|    |     |     |     | 165 |     |     |     |     |     | 170 |     |     |     |     | 175 |     |  |
| 25 | Tyr | Arg | Thr | Leu | Ser | Asp | Ala | Asp | Arg | Lys | Gly | Gly | Asn | Ser | Ser | Val |  |
|    |     |     |     | 180 |     |     |     |     | 185 |     |     |     |     | 190 |     |     |  |
| 30 | Lys | Leu | Glu | Ala | Gly | Leu | Ala | Asn | Thr | Ile | Thr | Ser | Phe | Ile | Asp | Lys |  |
|    |     | 195 |     |     |     |     |     | 200 |     |     |     |     | 205 |     |     |     |  |
| 35 | Gly | Gln | Asp | Asp | Arg | Gly | Pro | Val | Val | Arg | Lys | Gln | Arg | Tyr | Val | Phe |  |
|    | 210 |     |     |     |     |     | 215 |     |     |     |     | 220 |     |     |     |     |  |
| 40 | Asp | Ile | Ser | Ala | Leu | Glu | Lys | Asp | Gly | Leu | Leu | Gly | Ala | Glu | Leu | Arg |  |
|    | 225 |     |     |     |     |     | 230 |     |     |     | 235 |     |     |     |     | 240 |  |
| 45 | Ile | Leu | Arg | Lys | Lys | Pro | Ser | Asp | Thr | Ala | Lys | Pro | Ala | Ala | Pro | Gly |  |
|    |     |     |     | 245 |     |     |     |     |     | 250 |     |     |     |     | 255 |     |  |
| 50 | Gly | Gly | Arg | Ala | Ala | Gln | Leu | Lys | Leu | Ser | Ser | Cys | Pro | Ser | Gly | Arg |  |
|    |     |     | 260 |     |     |     |     |     | 265 |     |     |     |     |     | 270 |     |  |
| 55 | Gln | Pro | Ala | Ser | Leu | Leu | Asp | Val | Arg | Ser | Val | Pro | Gly | Leu | Asp | Gly |  |
|    |     | 275 |     |     |     |     |     | 280 |     |     |     |     | 285 |     |     |     |  |
| 60 | Ser | Gly | Trp | Glu | Val | Phe | Asp | Ile | Trp | Lys | Leu | Phe | Arg | Asn | Phe | Lys |  |
|    |     | 290 |     |     |     |     | 295 |     |     |     |     | 300 |     |     |     |     |  |
| 65 | Asn | Ser | Ala | Gln | Leu | Cys | Leu | Glu | Leu | Glu | Ala | Trp | Glu | Arg | Gly | Arg |  |
|    | 305 |     |     |     |     | 310 |     |     |     |     | 315 |     |     |     |     | 320 |  |
| 70 | Ala | Val | Asp | Leu | Arg | Gly | Leu | Gly | Phe | Asp | Arg | Ala | Ala | Arg | Gln | Val |  |
|    |     |     |     | 325 |     |     |     |     |     | 330 |     |     |     |     | 335 |     |  |

**EP 1 074 620 A1**

```

His Glu Lys Ala Leu Phe Leu Val Phe Gly Arg Thr Lys Lys Arg Asp
      340                               345                               350

5
Leu Phe Phe Asn Glu Ile Lys Ala Arg Ser Gly Gln Asp Asp Lys Thr
      355                               360                               365

10
Val Tyr Glu Tyr Leu Phe Ser Gln Arg Arg Lys Arg Arg Ala Pro Leu
      370                               375                               380

Ala Thr Arg Gln Gly Lys Arg Pro Ser Lys Asn Leu Lys Ala Arg Cys
      385                               390                               395                               400

15
Ser Arg Lys Ala Leu His Val Asn Phe Lys Asp Met Gly Trp Asp Asp
      405                               410                               415

20
Trp Ile Ile Ala Pro Leu Glu Tyr Glu Ala Phe His Cys Glu Gly Leu
      420                               425                               430

Cys Glu Phe Pro Leu Arg Ser His Leu Glu Pro Thr Asn His Ala Val
      435                               440                               445

25
Ile Gln Thr Leu Met Asn Ser Met Asp Pro Glu Ser Thr Pro Pro Thr
      450                               455                               460

30
Xaa Cys Val Pro Thr Arg Leu Ser Pro Ile Ser Ile Leu Phe Ile Asp
      465                               470                               475                               480

35
Ser Ala Asn Asn Val Val Tyr Lys Gln Tyr Glu Asp Met Val Val Glu
      485                               490                               495

Ser Cys Gly Cys Arg
      500

40

45
<210> 3
<211> 2272
<212> DNA
<213> Homo sapiens

50
<220>
<221> CDS
<222> (128)..(1183)

55
<400> 3

```



EP 1 074 620 A1

caaggagcca tgccagctgg acacacactt cttccagggc ctctggcagc caggacagag 60

5 ttgagaccac agctgttgag accctgagcc ctgagctctgt attgctcaag aagggccttc 120

10 cccagca atg acc tcc tca ttg ctt ctg gcc ttt ctc ctc ctg gct cca 169

Met Thr Ser Ser Leu Leu Leu Ala Phe Leu Leu Leu Ala Pro  
1 5 10

15 acc aca gtg gcc act ccc aga gct ggc ggt cag tgt cca gca tgt ggg 217

Thr Thr Val Ala Thr Pro Arg Ala Gly Gly Gln Cys Pro Ala Cys Gly  
15 20 25 30

20 ggg ccc acc ttg gaa ctg gag agc cag cgg gag ctg ctt ctt gat ctg 265

Gly Pro Thr Leu Glu Leu Glu Ser Gln Arg Glu Leu Leu Leu Asp Leu  
25 35 40 45

gcc aag aga agc atc ttg gac aag ctg cac ctc acc cag cgc cca aca 313

30 Ala Lys Arg Ser Ile Leu Asp Lys Leu His Leu Thr Gln Arg Pro Thr  
50 55 60

ctg aac cgc cct gtg tcc aga gct gct ttg agg act gca ctg cag cac 361

35 Leu Asn Arg Pro Val Ser Arg Ala Ala Leu Arg Thr Ala Leu Gln His  
65 70 75

40 ctc cac ggg gtc cca cag ggg gca ctt cta gag gac aac agg gaa cag 409

Leu His Gly Val Pro Gln Gly Ala Leu Leu Glu Asp Asn Arg Glu Gln  
80 85 90

45 gaa tgt gaa atc atc agc ttt gct gag aca ggc ctc tcc acc atc aac 457

Glu Cys Glu Ile Ile Ser Phe Ala Glu Thr Gly Leu Ser Thr Ile Asn  
95 100 105 110

50 cag act cgt ctt gat ttt cac ttc tcc tct gat aga act gct ggt gac 505

Gln Thr Arg Leu Asp Phe His Phe Ser Ser Asp Arg Thr Ala Gly Asp  
55 115 120 125

EP 1 074 620 A1

agg gag gtc cag cag gcc agt ctc atg ttc ttt gtg cag ctc cct tcc 553

5 Arg Glu Val Gln Gln Ala Ser Leu Met Phe Phe Val Gln Leu Pro Ser  
130 135 140

aat acc act tgg acc ttg aaa gtg aga gtc ctt gtg ctg ggt cca cat 601

10 Asn Thr Thr Trp Thr Leu Lys Val Arg Val Leu Val Leu Gly Pro His  
145 150 155

aat acc aac ctc acc ttg gct act cag tac ctg ctg gag gtg gat gcc 649

15 Asn Thr Asn Leu Thr Leu Ala Thr Gln Tyr Leu Leu Glu Val Asp Ala  
160 165 170

20 agt ggc tgg cat caa ctc ccc cta ggg cct gaa gct caa gct gcc tgc 697

Ser Gly Trp His Gln Leu Pro Leu Gly Pro Glu Ala Gln Ala Ala Cys  
175 180 185 190

25 agc cag ggg cac ctg acc ctg gag ctg gta ctt gaa ggc cag gta gcc 745

Ser Gln Gly His Leu Thr Leu Glu Leu Val Leu Glu Gly Gln Val Ala  
30 195 200 205

cag agc tca gtc atc ctg ggt gga gct gcc cat agg cct ttt gtg gca 793

35 Gln Ser Ser Val Ile Leu Gly Gly Ala Ala His Arg Pro Phe Val Ala  
210 215 220

gcc cgg gtg aga gtt ggg ggc aaa cac cag att cac cga cga ggc atc 841

40 Ala Arg Val Arg Val Gly Gly Lys His Gln Ile His Arg Arg Gly Ile  
225 230 235

45 gac tgc caa gga ggg tcc agg atg tgc tgt cga caa gag ttt ttt gtg 889

Asp Cys Gln Gly Gly Ser Arg Met Cys Cys Arg Gln Glu Phe Phe Val  
240 245 250

50 gac ttc cgt gag att ggc tgg cac gac tgg atc atc cag cct gag ggc 937

Asp Phe Arg Glu Ile Gly Trp His Asp Trp Ile Ile Gln Pro Glu Gly  
55 255 260 265 270

EP 1 074 620 A1

tac gcc atg aac ttc tgc ata ggg cag tgc cca cta cac ata gca ggc 985  
 5 Tyr Ala Met Asn Phe Cys Ile Gly Gln Cys Pro Leu His Ile Ala Gly  
 275 280 285  
 atg cct ggt att gct gcc tcc ttt cac act gca gtg ctc aat ctt ctc 1033  
 10 Met Pro Gly Ile Ala Ala Ser Phe His Thr Ala Val Leu Asn Leu Leu  
 290 295 300  
 aag gcc aac aca gct gca ggc acc act gga ggg ggc tca nnn tgt gta 1081  
 15 Lys Ala Asn Thr Ala Ala Gly Thr Thr Gly Gly Gly Ser Xaa Cys Val  
 305 310 315  
 ccc acg gcc cgg cgc ccc ctg tct ctg ctc tat tat gac agg gac agc 1129  
 20 Pro Thr Ala Arg Arg Pro Leu Ser Leu Leu Tyr Tyr Asp Arg Asp Ser  
 320 325 330  
 25 aac att gtc aag act gac ata cct gac atg gta gta gag gcc tgt ggg 1177  
 Asn Ile Val Lys Thr Asp Ile Pro Asp Met Val Val Glu Ala Cys Gly  
 30 335 340 345 350  
 tgc agt tagtctatgt gtggtatggg cagcccaagg ttgcatggga aaacacgccc 1233  
 35 Cys Ser  
 ctacagaagt gcacttcctt gagaggaggg aatgacctca ttctctgtcc agaattgtgga 1293  
 40 ctccctcttc ctgagcatct tatggaaatt accccacctt tgacttgaag aaaccttcat 1353  
 ctaaagcaag tcaactgtgcc atcttctga ccactacct ctttcttagg gcatagtcca 1413  
 45 tcccgctagt ccatcccgct agccccactc cagggactca gacctctc caaccatgag 1473  
 50 caatgccatc tggttcccag gcaaagacac ccttagctca cctttaatag accccataac 1533  
 55

EP 1 074 620 A1

ccactatgcc ttctgtcct ttctactcaa tggccccac tccaagatga gttgacacaa 1593

5 ccccttcccc caatttttgt ggatctccag agagggcctt ctttggattc accaaagttt 1653

10 agatcactgc tgcccaaaat agaggcttac ctacccccct ctttgttgtg agccctgtc 1713

cttcttagtt gtccaggtga actactaaag ctctctttgc ataccttcac ccattttttg 1773

15 tccttctctg cttttctcta tgcccttaag gggtgacttg cctgagctct atcacctgag 1833

20 ctccccctgcc ctctggcttc ctgtgaggt cagggcattt cttatccctg ttccctctct 1893

25 gtctagggtgt catggttctg tgtaactgtg gctattctgt gtccctacac tacctggcta 1953

cccccttcca tggtcccccage tctgcctaca ttctgatttt tttttttttt ttttttttga 2013

30 aaagttaaaa attccttaat tttttattcc tgggtaccact accacaattt acagggcaat 2073

35 atacctgatg taatgaaaag aaaaagaaaa agacaaagct acaacagata aaagacctca 2133

ggaatgtaca tctaattgac actacattgc attaatcaat agctgcactt ttgcaaact 2193

40 gtggctatga cagtcctgaa caagaagggt ttctgttta agctgcagta acttttctga 2253

45 ctatggatca tegtccctt 2272

50 <210> 4  
<211> 352  
<212> PRT

55 <213> Homo sapiens

EP 1 074 620 A1

<400> 4  
Met Thr Ser Ser Leu Leu Leu Ala Phe Leu Leu Leu Ala Pro Thr Thr  
1 5 10 15  
5  
Val Ala Thr Pro Arg Ala Gly Gly Gln Cys Pro Ala Cys Gly Gly Pro  
20 25 30  
10  
Thr Leu Glu Leu Glu Ser Gln Arg Glu Leu Leu Leu Asp Leu Ala Lys  
35 40 45  
Arg Ser Ile Leu Asp Lys Leu His Leu Thr Gln Arg Pro Thr Leu Asn  
15 50 55 60  
Arg Pro Val Ser Arg Ala Ala Leu Arg Thr Ala Leu Gln His Leu His  
65 70 75 80  
20  
Gly Val Pro Gln Gly Ala Leu Leu Glu Asp Asn Arg Glu Gln Glu Cys  
85 90 95  
25  
Glu Ile Ile Ser Phe Ala Glu Thr Gly Leu Ser Thr Ile Asn Gln Thr  
100 105 110  
Arg Leu Asp Phe His Phe Ser Ser Asp Arg Thr Ala Gly Asp Arg Glu  
30 115 120 125  
Val Gln Gln Ala Ser Leu Met Phe Phe Val Gln Leu Pro Ser Asn Thr  
130 135 140  
35  
Thr Trp Thr Leu Lys Val Arg Val Leu Val Leu Gly Pro His Asn Thr  
145 150 155 160  
Asn Leu Thr Leu Ala Thr Gln Tyr Leu Leu Glu Val Asp Ala Ser Gly  
40 165 170 175  
Trp His Gln Leu Pro Leu Gly Pro Glu Ala Gln Ala Ala Cys Ser Gln  
45 180 185 190  
Gly His Leu Thr Leu Glu Leu Val Leu Glu Gly Gln Val Ala Gln Ser  
195 200 205  
50  
Ser Val Ile Leu Gly Gly Ala Ala His Arg Pro Phe Val Ala Ala Arg  
210 215 220  
Val Arg Val Gly Gly Lys His Gln Ile His Arg Arg Gly Ile Asp Cys  
55 225 230 235 240

Gln Gly Gly Ser Arg Met Cys Cys Arg Gln Glu Phe Phe Val Asp Phe  
 245 250 255  
 5 Arg Glu Ile Gly Trp His Asp Trp Ile Ile Gln Pro Glu Gly Tyr Ala  
 260 265 270  
 10 Met Asn Phe Cys Ile Gly Gln Cys Pro Leu His Ile Ala Gly Met Pro  
 275 280 285  
 Gly Ile Ala Ala Ser Phe His Thr Ala Val Leu Asn Leu Leu Lys Ala  
 15 290 295 300  
 Asn Thr Ala Ala Gly Thr Thr Gly Gly Gly Ser Xaa Cys Val Pro Thr  
 305 310 315 320  
 20 Ala Arg Arg Pro Leu Ser Leu Leu Tyr Tyr Asp Arg Asp Ser Asn Ile  
 325 330 335  
 25 Val Lys Thr Asp Ile Pro Asp Met Val Val Glu Ala Cys Gly Cys Ser  
 340 345 350

### Claims

1. Protein selected from the members of the TGF- $\beta$  superfamily,  
 characterized in that the protein is necessarily monomeric due to substitution or deletion of a cysteine which is  
 responsible for dimer formation.
2. Protein according to claim 1,  
 characterized in that the protein is a mature protein or a biologically active part or variant thereof.
3. Protein according to any one of the preceeding claims,  
 characterized in that the protein contains at least the 7 cysteine region characteristic for the TGF- $\beta$  protein super-  
 family.
4. Protein according to claim 3,  
 characterized in that it contains a consensus sequence according to Formula I: C(Y)<sub>25-29</sub>CYYYC(Y)<sub>25-35</sub>XC  
 (Y)<sub>27-34</sub>CYC or Formula II: C(Y)<sub>28</sub>CYYYC(Y)<sub>30-32</sub>XC(Y)<sub>31</sub>CYC, wherein C denotes cysteine, Y denotes any amino  
 acid and X denotes any amino acid except cysteine.
5. Protein according to any one of claims 1 to 4,  
 characterized in that the protein is a morphogenetic protein.
6. Protein according to any one of the preceeding claims,  
 characterized in that the proteins belongs to the TGF- $\beta$ , BMP, GDF, activin or GDNF family.
7. Protein according to claim 6,  
 characterized in that the protein is MP52 (GDF5) or a biologically active part or variant thereof.
8. Protein according to any one of the preceeding claims,

- characterized in that it comprises the amino acid sequence according to SEQ.ID.NO.2 or a part thereof.
9. Protein according to claim 6,  
characterized in that the protein is MP121 or a biologically active part or variant thereof.
  10. Protein according to claim 9,  
characterized in that it comprises the amino acid sequence according to SEQ.ID.NO.4 or a part thereof.
  11. Protein according to any one of claims 1 to 10,  
characterized in that the cysteine residue is substituted by an amino acid selected from the group of alanine, serine, threonine, leucine, isoleucine, glycine and valine.
  12. Protein according to any one of claims 1 to 11,  
characterized in that it contains additional amino acids that facilitate or mediate the transfer and localization of the protein in a certain tissue.
  13. Nucleic acid,  
characterized in that it encodes a protein according to any one of claims 1 to 12.
  14. Nucleic acid according to claim 13,  
characterized in that it is a DNA.
  15. Nucleic acid according to claim 13 or 14,  
characterized in that it contains a sequence as shown in SEQ.ID.NO.1 or a fragment thereof.
  16. Nucleic acid according to claim 13 or 14,  
characterized in that it contains a sequence as shown in SEQ.ID.NO.3 or a fragment thereof.
  17. Nucleic acid according to any one of claims 13 to 16,  
characterized in that it further contains suitable expression control sequences facilitating and/or driving expression of the encoded protein.
  18. Expression vector,  
characterized in that it contains a nucleic acid according to any one of claims 13 to 17 in a suitable vector system.
  19. Expression vector according to claim 18,  
characterized in that the vector system is suitable for prokaryotic expression.
  20. Host cell,  
characterized in that it contains a nucleic acid according to any one of claims 13 to 17 or an expression vector according to claims 18 or 19 and upon expression of said nucleic acid or vector is able to produce a monomeric protein according to any one of claims 1 to 12.
  21. Host cell according to claim 20,  
characterized in that it is a prokaryotic host cell.
  22. Host cell according to claim 20,  
characterized in that it is an embryonal cell.
  23. Pharmaceutical composition,  
characterized in that it contains at least one protein according to any one of claims 1 to 12 or at least one nucleic acid according to any one of claims 13 to 17, at least one expression vector according to any one of claims 18 or 19 or at least one host cell according to claim 20 or 22.
  24. Pharmaceutical composition according to claim 23,  
characterized in that the protein and/or nucleic acid are contained in and/or on a biocompatible matrix material.
  25. Pharmaceutical composition according to claim 24,

characterized in that the matrix material is biodegradable.

26. Pharmaceutical composition according to claims 24 or 25,  
characterized in that the matrix material is itself osteogenically active.
27. Pharmaceutical composition according to any one of claims 23 to 26,  
for the prevention or therapy of diseases for which also the dimeric form of the protein would be indicated.
28. Pharmaceutical composition according to claim 27,  
for prevention or therapy of diseases associated with bone and/or cartilage damage or affecting bone and/or cartilage disease or situations in which cartilage and/or bone growth is desirable or for spinal fusion.
29. Pharmaceutical composition according to claim 27,  
for prevention or therapy of damaged or diseased tissue associated with connective tissue including tendon and/or ligament, periodontal or dental tissue including dental implants, neural tissue including CNS tissue and neuropathological situations, tissue of the sensory system, liver, pancreas, cardiac, blood vessel, renal, uterine and thyroid tissue, skin, mucous membranes, endothelium, epithelium, for promotion or induction of nerve growth, tissue regeneration, angiogenesis, wound healing including ulcers, burns, injuries or skin grafts, induction of proliferation of progenitor cells or bone marrow cells, for maintenance of a state of proliferation or differentiation, for treatment or preservation of tissue or cells for organ or tissue transplantation, for integrity of gastrointestinal lining, for treatment of disturbances in fertility, contraception or pregnancy.
30. Pharmaceutical composition according to any one of claims 23 to 29 for surgical local application, topical or systemic application.
31. Pharmaceutical composition according to any one of claims 23 to 30  
characterized in that it further contains pharmacologically acceptable auxiliary substances.
32. Pharmaceutical composition according to any one of claims 30 or 31,  
characterized in that the composition is injectable.
33. Pharmaceutical composition according to any one of claims 30 to 32,  
characterized in that it is contained in a vehicle that allows to direct and release the composition to a determined site of action.
34. Pharmaceutical composition according to claim 33,  
characterized in that the vehicle is selected from liposomes, nanospheres, larger implantable containers and micropumps.
35. Use of a pharmaceutical composition according to any one of claims 23 to 34 for the prevention or treatment of any indications of the dimeric form of the protein.



Fig. 1 A

Name: MP52, dimeric form

Formula

 $C_{1184}H_{1844}N_{330}O_{350}S_{22}$ 

Molecular weight

26994 Dalton

Amino acid composition

238 amino acids

Disulfide bond

7 bonds

## Primary structure





Fig. 1 B





European Patent  
Office

# PARTIAL EUROPEAN SEARCH REPORT

Application Number

which under Rule 45 of the European Patent Convention EP 99 11 5613  
shall be considered, for the purposes of subsequent  
proceedings, as the European search report

| DOCUMENTS CONSIDERED TO BE RELEVANT  |  |                                  |  |
|--|--|----------------------------------|--|
| Category   | Citation of document with indication, where appropriate, of relevant passages  | Relevant to claim                | CLASSIFICATION OF THE APPLICATION (Int.Cl.7) |
| X  | HÜSKEN-HINDI, PETRA ET AL: "Monomeric activin A retains high receptor binding affinity but exhibits low biological activity."<br>JOURNAL OF BIOLOGICAL CHEMISTRY, (1994)<br>VOL. 269, NO. 30, PP. 19380-19384<br>24 July 1994 (1994-07-24), XP002111996  | 1-6,11,<br>13,14,<br>17,18,20    | C12N15/12<br>C07K14/495<br>A61K38/18         |
| Y  | * the whole document *   | 7-10,12,<br>15,16,<br>19,21-35   |  |
| X  | AMATAYAKUL-CHANTLER, SUPAVADEE (1) ET AL:<br>"(Ser-77)Transforming growth factor-beta-1: Selective biological activity and receptor binding in mink lung epithelial cells."<br>JOURNAL OF BIOLOGICAL CHEMISTRY, (1994)<br>VOL. 269, NO. 44, PP. 27687-27691<br>4 November 1994 (1994-11-04), XP002111995 | 1-6,11,<br>13,14,<br>17-22       |  |
| Y  | * the whole document *   | 7-10,12,<br>15,16,<br>23-35      |  |
|  |  |                                  | TECHNICAL FIELDS SEARCHED (Int.Cl.7)         |
|  |  |                                  | C07K<br>C12N<br>A61K                         |
| <b>INCOMPLETE SEARCH</b><br>The Search Division considers that the present application, or one or more of its claims, does/do not comply with the EPC to such an extent that a meaningful search into the state of the art cannot be carried out, or can only be carried out partially, for these claims.<br>Claims searched completely:<br>Claims searched incompletely:<br>Claims not searched:<br>Reason for the limitation of the search:<br>Although claim 35 is directed to a method of treatment of the human/animal body (Article 52(4) EPC), the search has been carried out and based on the alleged effects of the composition. |  |                                  |  |
| Place of search  |  | Date of completion of the search | Examiner                                     |
| THE HAGUE  |  | 10 January 2000                  | Hix, R                                       |
| CATEGORY OF CITED DOCUMENTS<br>X : particularly relevant if taken alone<br>Y : particularly relevant if combined with another document of the same category<br>A : technological background<br>O : non-written disclosure<br>P : intermediate document<br>T : theory or principle underlying the invention<br>E : earlier patent document, but published on, or after the filing date<br>D : document cited in the application<br>L : document cited for other reasons<br>& : member of the same patent family, corresponding document   |  |                                  |  |

EPO FORM 1503 03/02 (PMA/C07)

European Patent  
Office

## PARTIAL EUROPEAN SEARCH REPORT

Application Number  
EP 99 11 5613

| DOCUMENTS CONSIDERED TO BE RELEVANT |  |                          | CLASSIFICATION OF THE APPLICATION (Int.Cl.7) |
|-------------------------------------|--|--------------------------|--|
| Category                            | Citation of document with indication, where appropriate, of relevant passages  | Relevant to claim        |  |
| X                                   | BRUNNER, AMY M. ET AL: "Site-directed mutagenesis of glycosylation sites in the transforming growth factor-beta-1 ( TGF - beta -1) and TGF - beta -2 (414) precursors and of cysteine residues within mature TGF - beta -1: Effects on secretion and bioactivity."<br>MOLECULAR ENDOCRINOLOGY, (1992) VOL. 6, NO. 10, PP. 1691-1700. , XP000863262 | 1-6,11, 13,14, 17,18,20  |  |
| Y                                   | * the whole document *   | 7-10,12, 15,16, 19,21-35 |  |
| X                                   | BRUNNER A M ET AL: "SITE-DIRECTED MUTAGENESIS OF CYSTEINE RESIDUES IN THE PRO REGION OF THE TRANSFORMING GROWTH FACTOR BETA-1 PRECURSOR EXPRESSION AND CHARACTERIZATION OF MUTANT PROTEINS."<br>J BIOL CHEM. (1989) 264 (23), 13660-13664. , XP000857484<br>* the whole document *   | 1,3-6                    | TECHNICAL FIELDS SEARCHED (Int.Cl.7)         |
| Y                                   | WO 94 17099 A (CELTRIX PHARMA)<br>4 August 1994 (1994-08-04)<br>* the whole document *   | 1-35                     |  |
| Y                                   | WO 95 04819 A (BIOPH BIOTECH ENTW PHARM GMBH) 16 February 1995 (1995-02-16)<br>* the whole document *  | 1-35                     |  |
| Y                                   | WO 96 01316 A (BIOPH BIOTECH ENTW PHARM GMBH ;HOETTEN GERTRUD (DE); NEIDHARDT,HEL) 18 January 1996 (1996-01-18)<br>* the whole document *  | 1-35                     |  |
| Y                                   | WO 95 16035 A (GENETICS INST ;HARVARD COLLEGE (US)) 15 June 1995 (1995-06-15)<br>* the whole document *  | 1-35                     |  |
|                                     | ---  |                          |  |
|                                     | ---<br>-/--  |                          |  |

EPO FORM 1533 03.02 (P04C10)



European Patent  
Office

## PARTIAL EUROPEAN SEARCH REPORT

Application Number

EP 99 11 5613

| DOCUMENTS CONSIDERED TO BE RELEVANT |   |                   | CLASSIFICATION OF THE APPLICATION (Int.Cl.7) |
|-------------------------------------|---|-------------------|--|
| Category                            | Citation of document with indication, where appropriate, of relevant passages   | Relevant to claim |  |
| Y                                   | EP 0 915 168 A (HOECHST MARION ROUSSEL LTD) 12 May 1999 (1999-05-12)<br>* the whole document *  | 1-35              |  |
| Y,D                                 | WO 97 03188 A (BIOPH BIOTECH ENTW PHARM GMBH ;HOETTEN GERTRUD (DE); POHL JENS (DE)) 30 January 1997 (1997-01-30)<br>* the whole document *  | 1-35              |  |
| A,D                                 | DAOPIN S ET AL: "CRYSTAL STRUCTURE OF TRANSFORMING GROWTH FACTOR-BETA2: UNUSUAL FOLD FOR THE SUPERFAMILY" SCIENCE,US,AMERICAN ASSOCIATION FOR THE ADVANCEMENT OF SCIENCE,, vol. 257, page 369-373 XP000857489 ISSN: 0036-8075<br>* the whole document *                           |                   | TECHNICAL FIELDS SEARCHED (Int.Cl.7)         |
| A,D                                 | M.P. SCHLUNEGGER ET AL: "An unusual feature revealed by the crystal structure at 2.2 Å resolution of human transforming growth factor-beta 2" NATURE,GB,MACMILLAN JOURNALS LTD. LONDON, vol. 358, no. 358, page 430-434-434 XP002110204 ISSN: 0028-0836<br>* the whole document * |                   |  |

EPO FORM 1503 03 82 (p04c10)

**ANNEX TO THE EUROPEAN SEARCH REPORT  
ON EUROPEAN PATENT APPLICATION NO.**

EP 99 11 5613

This annex lists the patent family members relating to the patent documents cited in the above-mentioned European search report.  
The members are as contained in the European Patent Office EDP file on  
The European Patent Office is in no way liable for these particulars which are merely given for the purpose of information.

10-01-2000

| Patent document<br>cited in search report | Publication<br>date | Patent family<br>member(s) | Publication<br>date |
|---|---------------------|----------------------------|---------------------|
| WO 9417099 A                              | 04-08-1994          | US 5420243 A               | 30-05-1995          |
|   |                     | AU 697916 B                | 22-10-1998          |
|   |                     | AU 4097797 A               | 08-01-1998          |
|   |                     | AU 685084 B                | 15-01-1998          |
|   |                     | AU 6093294 A               | 15-08-1994          |
|   |                     | CA 2153789 A               | 04-08-1994          |
|   |                     | EP 0791011 A               | 27-08-1997          |
|   |                     | JP 8510443 T               | 05-11-1996          |
|   |                     | US 5658883 A               | 19-08-1997          |
| WO 9504819 A                              | 16-02-1995          | DE 4420157 A               | 23-02-1995          |
|   |                     | AU 688362 B                | 12-03-1998          |
|   |                     | AU 7498694 A               | 28-02-1995          |
|   |                     | CA 2169171 A               | 16-02-1995          |
|   |                     | CN 1129013 A               | 14-08-1996          |
|   |                     | CZ 9600357 A               | 17-07-1995          |
|   |                     | EP 0713529 A               | 29-05-1996          |
|   |                     | HU 74271 A                 | 28-11-1996          |
|   |                     | JP 9501053 T               | 04-02-1997          |
|   |                     | NZ 271376 A                | 24-04-1997          |
|   |                     | US 5994094 A               | 30-11-1999          |
|   |                     | ZA 9405992 A               | 14-03-1995          |
| WO 9601316 A                              | 18-01-1996          | DE 19511243 A              | 04-01-1996          |
|   |                     | AU 2979895 A               | 25-01-1996          |
|   |                     | CN 1151758 A               | 11-06-1996          |
|   |                     | DE 19580745 D              | 11-03-1999          |
|   |                     | JP 10502527 T              | 10-03-1998          |
|   |                     | US 5807713 A               | 15-09-1998          |
|   |                     | ZA 9505444 A               | 14-02-1996          |
| WO 9516035 A                              | 15-06-1995          | AU 689184 B                | 26-03-1998          |
|   |                     | AU 1301395 A               | 27-06-1995          |
|   |                     | CA 2176942 A               | 15-06-1995          |
|   |                     | EP 0733109 A               | 25-09-1996          |
|   |                     | FI 962350 A                | 16-07-1996          |
|   |                     | JP 9506261 T               | 24-06-1997          |
|   |                     | NO 962304 A                | 04-06-1996          |
|   |                     | US 5658882 A               | 19-08-1997          |
| EP 0915168 A                              | 12-05-1999          | JP 9295945 A               | 18-11-1997          |
|   |                     | AU 2408497 A               | 19-11-1997          |
|   |                     | NO 985041 A                | 29-10-1998          |
|   |                     | CZ 9803449 A               | 17-03-1999          |
|   |                     | WO 9741250 A               | 06-11-1997          |
|   |                     | PL 329610 A                | 29-03-1999          |

EPO FORM P0459

For more details about this annex : see Official Journal of the European Patent Office, No. 12/82

